Autolus Therapeutics (NASDAQ:AUTL) Stock Price Up 3.7%

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s stock price was up 3.7% during mid-day trading on Thursday . The company traded as high as $5.25 and last traded at $5.02. Approximately 215,735 shares changed hands during trading, a decline of 86% from the average daily volume of 1,496,267 shares. The stock had previously closed at $4.84.

Analysts Set New Price Targets

A number of research analysts recently issued reports on AUTL shares. Truist Financial boosted their price target on Autolus Therapeutics from $10.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, April 9th. Needham & Company LLC restated a "buy" rating and set a $9.00 price target on shares of Autolus Therapeutics in a report on Friday, April 12th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Autolus Therapeutics has an average rating of "Moderate Buy" and an average price target of $8.16.

Autolus Therapeutics Stock Performance

The stock has a market capitalization of $1.28 billion, a P/E ratio of -4.13 and a beta of 1.90. The business has a 50-day moving average price of $5.95 and a 200 day moving average price of $5.08.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its earnings results on Thursday, March 14th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.18). As a group, research analysts forecast that Autolus Therapeutics plc will post -0.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of institutional investors have recently bought and sold shares of AUTL. Price T Rowe Associates Inc. MD bought a new position in Autolus Therapeutics in the 4th quarter worth $19,328,000. Perceptive Advisors LLC bought a new stake in Autolus Therapeutics during the fourth quarter valued at about $11,793,000. Laurion Capital Management LP bought a new stake in Autolus Therapeutics during the fourth quarter valued at about $2,850,000. Alyeska Investment Group L.P. bought a new stake in Autolus Therapeutics during the fourth quarter valued at about $2,782,000. Finally, Lynx1 Capital Management LP bought a new stake in Autolus Therapeutics during the third quarter valued at about $3,176,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.